Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA).

e15023Background: Studies in 2L metastatic colorectal cancer (mCRC) have survival ranging around 10-14 months (m). No study has averaged over 10cy. In daily practice, there is a subset of patients ...